4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEG… Read more
4D Molecular Therapeutics Inc (FDMT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.126x
Based on the latest financial reports, 4D Molecular Therapeutics Inc (FDMT) has a cash flow conversion efficiency ratio of -0.126x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.50 Million) by net assets ($368.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
4D Molecular Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how 4D Molecular Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
4D Molecular Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 4D Molecular Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Axis Bank Ltd GDR
IL:AXB
|
N/A |
|
Action Construction Equipment Limited
NSE:ACE
|
0.003x |
|
Fjordkraft Holding ASA
F:1ZK
|
-0.633x |
|
Beijing Water Business Doctor
SHE:300055
|
0.001x |
|
Sk Gas
KO:018670
|
0.070x |
|
Hootech Inc.
SHE:301026
|
N/A |
|
RWS Holdings plc
PINK:RWSPF
|
0.044x |
|
Hengxin Mobile Business
SHE:300081
|
-0.006x |
Annual Cash Flow Conversion Efficiency for 4D Molecular Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of 4D Molecular Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $510.61 Million | $-134.59 Million | -0.264x | -7.05% |
| 2023-12-31 | $307.83 Million | $-75.79 Million | -0.246x | +34.29% |
| 2022-12-31 | $231.34 Million | $-86.69 Million | -0.375x | -72.96% |
| 2021-12-31 | $319.11 Million | $-69.13 Million | -0.217x | -9.11% |
| 2020-12-31 | $256.39 Million | $-50.91 Million | -0.199x | -139.47% |
| 2019-12-31 | $-72.97 Million | $-36.71 Million | 0.503x | -14.60% |
| 2018-12-31 | $-27.59 Million | $-16.25 Million | 0.589x | +240.11% |
| 2017-12-31 | $-19.59 Million | $8.24 Million | -0.420x | -- |